Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
LA JOLLA, Calif., Feb. 27, 2017 -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today announced an oral presentation for its lead product candidate, tipifarnib, at the 15th International Congress on Targeted Anticancer Therapies (TAT 2017), taking place March 6-8, 2017 in Paris, France. The presentation will feature clinical data from the first stage of Kura Oncology’s tipifarnib Phase 2 program in HRAS mutant tumors.
Presentation:
Date & Time: March 6, 2017, 2:45 p.m. - 3:00 p.m. CET
Title of Presentation: Preliminary evidence of clinical activity with tipifarnib in squamous cell carcinomas of the head & neck (SCCHN) with HRAS mutations
Presenter: Alan L. Ho, M.D., Ph.D., Memorial Sloan Kettering Cancer Center
Session: Plenary Session 3: Phase 1 Studies - Completed or in progress (miscellaneous drugs & targets)
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials. The pipeline includes KO-947, an ERK inhibitor, and KO-539, an inhibitor of the menin-MLL protein-protein interactions. For additional information about Kura Oncology, please visit the company’s website at www.kuraoncology.com.
CONTACT INFORMATION INVESTOR CONTACT: Robert H. Uhl Managing Director Westwicke Partners, LLC (858) 356-5932 [email protected] MEDIA CONTACT: Mark Corbae Vice President Canale Communications (619) 849-5375 [email protected]
